A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR Depot (Octreotide Acetate) In Preventing Or Reducing The Severity Of Chemoradiation-Induced Diarrhea In Patients With Anal Or Rectal Cancer
Phase of Trial: Phase III
Latest Information Update: 19 Nov 2015
At a glance
- Drugs Octreotide (Primary)
- Indications Diarrhoea
- Focus Therapeutic Use
- 03 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Sep 2010 Actual end date (April 2010) added as reported by ClinicalTrials.gov.
- 27 May 2009 New trial record